» Articles » PMID: 25025942

Medical and Obstetric Complications Among Pregnant Women with Cystic Fibrosis

Overview
Publisher Elsevier
Date 2014 Jul 16
PMID 25025942
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The objective of this study was to estimate the nationwide prevalence of cystic fibrosis (CF) in pregnancy and determine what medical complications exist at delivery among pregnant women with CF.

Study Design: The Nationwide Inpatient Sample (NIS) was queried for all delivery-related discharges. Women with CF were identified by International Classification of Diseases, 9th revision, Clinical Modifications codes and compared with women without CF. The prevalence of selected severe medical complications was compared between the 2 groups (NIS years 2008-2010) using multivariable logistic regression and the linear change in prevalence of CF at delivery determined (NIS years 2000-2010).

Results: From 2000 to 2010, there was a significant linear increase in the prevalence of CF at delivery from 3.0 to 9.8 per 100,000 deliveries, in 2000 and 2010, respectively (R(2) = 0.92, P < .0001). From 2008-2010, there were 1119 deliveries to women with CF and 12,627,627 to women without CF. Women with CF were more likely to be white (P < .0001) and have diabetes (odds ratio [OR], 14.0; 95% confidence interval [CI], 11.8-16.7) or asthma (OR, 5.1; 95% CI, 4.3-6.1). Multivariable logistic regression demonstrated that women with CF were more likely to die (adjusted OR [aOR], 76.0; 95% CI, 31.6-183), require mechanical ventilation (aOR, 18.3; 95% CI, 10.8-31.2), or have pneumonia (aOR, 56.5; 95% CI, 43.2-74.1), acute renal failure (aOR, 17.3; 95% CI, 9.1-32.6), preterm labor (aOR, 2.2; 95% CI, 1.9-2.6), or an adverse composite CF outcome (aOR, 28.1; 95% CI, 21.8-36.3).

Conclusion: Pregnant women with CF are more likely to die, require mechanical ventilation, and have infectious complications compared with women without CF, although the absolute risks are low and these events are relatively rare.

Citing Articles

Anesthetic Management and Considerations for Cesarean Delivery in a Patient With Cystic Fibrosis.

Pham R, Mehdizadeh C, Baker C, Soloniuk L, Pasca I, Sinha A Case Rep Anesthesiol. 2025; 2025:6388254.

PMID: 39881848 PMC: 11774568. DOI: 10.1155/cria/6388254.


Investigating the role of CFTR in human and mouse myometrium.

Prendergast C, Wray S, Dungate D, Martin C, Vaida A, Brook E Curr Res Physiol. 2024; 7:100122.

PMID: 38501132 PMC: 10945125. DOI: 10.1016/j.crphys.2024.100122.


Reproductive Counseling and Care in Cystic Fibrosis: A Multidisciplinary Approach for a New Therapeutic Era.

McGlynn J, DeCelie-Germana J, Kier C, Langfelder-Schwind E Life (Basel). 2023; 13(7).

PMID: 37511919 PMC: 10381247. DOI: 10.3390/life13071545.


Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design.

Jain R, Magaret A, Vu P, Vandalfsen J, Keller A, Wilson A BMJ Open Respir Res. 2022; 9(1).

PMID: 35710144 PMC: 9204448. DOI: 10.1136/bmjresp-2022-001289.


Cystic Fibrosis-Related Diabetes Mellitus and Pregnancy: A Retrospective Study.

Davern R, Balan G, Kilcoyne C, Coveney C, Devine H, Walsh J Diabetes Ther. 2022; 13(3):481-487.

PMID: 35190969 PMC: 8934781. DOI: 10.1007/s13300-022-01223-1.